39 results on '"Loughran, Thomas P."'
Search Results
2. Lack of BLV and PTLV DNA sequences in the majority of patients with large granular lymphocyte leukaemia.
- Author
-
Perzova, Raisa N., Loughran, Thomas P., Dube, Syamalima, Ferrer, Jorge, Esteban, Eduardo, and Poiesz, Bernard J.
- Subjects
- *
LYMPHOMAS , *BOVINE leukemia virus , *RETROVIRUSES - Abstract
The primate T-cell lymphoma/leukaemia viruses (PTLV) and bovine leukaemia virus (BLV) comprise a unique genus of retroviruses, infection with which induces seroreactivity in the host against conserved epitopes in their p24 gag and gp21 env cognate proteins. Herein, we have confirmed this serocrossreactivity. Patients with large granular lymphocyte (LGL) leukaemia have frequent seroreactivity to the p24 and gp21 env proteins of human T-cell lymphoma/leukaemia virus I (HTLV-I), one of the species in the genus. However, only a small minority of patients are actually infected with prototypic HTLV-I or HTLV-II, another species within the group. In an attempt to determine whether LGL leukaemia might be associated with other members of the PTLV/BLV genus, we examined the peripheral blood mononuclear cell DNA of 22 HTLV p24 and/or gp21 seropositive LGL leukaemia patients via PCR using degenerate and specific primer pair/probe systems capable of detecting all known members of the PTLV/BLV genus. None of the samples was positive. These data indicate that although HTLV-II may be associated with some cases of LGL leukaemia most patients are not infected with a PTLV or BLV virus. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
3. T-cell intestinal lymphoma associated with celiac sprue.
- Author
-
Loughran, Thomas P., Kadin, Marshall E., Deeg, Joachim, Loughran, T P Jr, Kadin, M E, and Deeg, H J
- Subjects
- *
SPRUE , *POLYMORPHISM (Crystallography) , *INTESTINAL tumors , *CELIAC disease complications , *BRAIN tumors , *SMALL intestine , *LYMPH nodes , *LYMPHOMAS , *T cells - Abstract
A patient with a long history of celiac sprue developed a pleomorphic intestinal lymphoma. Cell suspensions of tumor cells and immunoperoxidase labeling of cell surface antigens in frozen tissue sections clearly showed the lymphoma to be of T-cell origin, despite the presence of other nontumor cells bearing enzyme markers of histiocytes. These findings may have important implications on the cellular origin of lymphomas developing in patients with celiac sprue. [ABSTRACT FROM AUTHOR]
- Published
- 1986
- Full Text
- View/download PDF
4. Polyarthritis and Neutropenia Associated with Circulating Large Granular Lymphocytes.
- Author
-
Jack Wallis, Wayne, Loughran, Thomas P., Kadin, Marshall E., Clark, Edward A., and Starkebaum, Gordon A.
- Subjects
- *
LYMPHOCYTES , *KILLER cells , *ARTHRITIS , *NEUTROPENIA - Abstract
Examines the circulating large granular lymphocytes with a phenotype attributed to immature natural killer cells in patients with polyarthritis and neutropenia. Materials and methodology of the study; Case reports of the patients; Discussion on the results of the study.
- Published
- 1985
- Full Text
- View/download PDF
5. Perspectives in the treatment of LGL leukemia
- Author
-
Burks, Eric J. and Loughran, Thomas P.
- Published
- 2005
- Full Text
- View/download PDF
6. Large Granular Lymphocyte Leukemia and Precapillary Pulmonary Hypertension.
- Author
-
Cherel, Brieuc, Humbert, Marc, LeBlanc, Francis R., Zambello, Renato, Hamidou, Mohamed, Lifermann, François, Montani, David, Leoncin, Matteo, Decaux, Olivier, Pastoret, Cedric, Le Bourgeois, Amandine, Dominique, Stéphane, Chabanne, Céline, Loughran, Thomas P., Lamy, Thierry, LeBlanc, Francis, and Loughran, Thomas P Jr
- Subjects
- *
PULMONARY hypertension , *LEUKEMIA , *LYMPHOCYTES , *AUTOIMMUNE hemolytic anemia , *ATRIAL septal defects , *LYSIS - Abstract
To the Editor: Large granular lymphocyte (LGL) leukemia belongs to the chronic mature lymphoproliferative disorders of the T/natural killer (NK) lineage.[1] T-LGL leukemia, which accounts for 85% of cases, and chronic lymphoproliferative disorder of NK cells (CLPD-NK), are indolent diseases with the same clinical and biological features.[1] Overall 10-year survival of patients with T- and NK-LGL leukemia is about 70%, and the estimated frequency is 2% to 5% of chronic lymphoproliferative diseases in North America and 5% to 6% in Asia.[2] Clinical presentations are related mainly to recurrent bacterial infections associated with neutropenia and/or anemia. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
7. Diagnosing large granular lymphocyte leukemia is bloody difficult.
- Author
-
Watters, Rebecca J. and Loughran, Thomas P.
- Subjects
- *
LYMPHOCYTES , *LEUKEMIA diagnosis , *NEUTROPENIA , *HEMOLYTIC anemia , *IMMUNOPHENOTYPING , *LEUCOCYTOSIS - Abstract
The article discusses research which investigated large granular lymphocyte (LGL) leukemia diagnosis, conducted by B. Bockorny and colleagues, published within the issue. Topics explored include the clinical characteristics of LGL leukemia, the hematological conditions like neutropenia and hemolytic anemia that LGL leukemia patients tend to suffer, and the effectiveness of peripheral blood immunophenotyping as a diagnostic tool for the condition.
- Published
- 2013
- Full Text
- View/download PDF
8. Potential clinical application of imatinib mesylate in patients with leukemic large granular lymphocytes.
- Author
-
Yang, Jun and Loughran, Thomas P.
- Subjects
- *
T cells , *HEMATOPOIETIC stem cell transplantation , *PLATELET-derived growth factor , *PROTEIN-tyrosine kinases , *CHRONIC myeloid leukemia , *PATIENTS - Abstract
In this article the authors comment on the study by Fedele and colleagues on the expansion of cytotoxic T lymphocyte (CTL) in allogeneic hematopoietic stem cell transplant recipients. The authors predict that the platelet-derived growth factor receptor (PDGFR) and receptor tyrosine kinases (RTKs) may play a role in large granular lymphocyte (LGL) leukemia patients. However, there is an expansion of LGLs in chronic myeloid leukemia (CML) patients which are treated wtih RTK inhibitors.
- Published
- 2011
- Full Text
- View/download PDF
9. Off-target effects of tyrosine kinase inhibitors: Beauty or the Beast?
- Author
-
Zhang, Ranran and Loughran, Thomas P.
- Subjects
- *
PROTEIN-tyrosine kinase inhibitors , *LEUKEMIA treatment , *MYELOID leukemia , *LYMPHOCYTES , *PROTEIN binding - Abstract
In this article the authors discuss the effects of tyrosine kinase inhibitors (TKIs) in treating patients with chronic myeloid leukemia (CML), and relates it to the study of J. J. Powers and colleagues on the correlation of large granular lymphocytes (LGL) expansion in CML patients treated with TKIs. They state that TKIs have been used to target breakpoint cluster region-abelson (BCR-ABL) protein fusion. The study showed that LGL population was only identified in patients treated with dasatinib.
- Published
- 2011
- Full Text
- View/download PDF
10. Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia.
- Author
-
Khokhlatchev, Andrei V., Sharma, Arati, Deering, Tye G., Shaw, Jeremy J. P., Costa‐Pinheiro, Pedro, Golla, Upendarrao, Annageldiyev, Charyguly, Cabot, Myles C., Conaway, Mark R., Tan, Su‐Fern, Ung, Johnson, Feith, David J., Loughran, Thomas P., Claxton, David F., Fox, Todd E., and Kester, Mark
- Abstract
Despite several new therapeutic options for acute myeloid leukemia (AML), disease relapse remains a significant challenge. We have previously demonstrated that augmenting ceramides can counter various drug‐resistance mechanisms, leading to enhanced cell death in cancer cells and extended survival in animal models. Using a nanoscale delivery system for ceramide (ceramide nanoliposomes, CNL), we investigated the effect of CNL within a standard of care venetoclax/cytarabine (Ara‐C) regimen. We demonstrate that CNL augmented the efficacy of venetoclax/cytarabine in in vitro, ex vivo, and in vivo models of AML. CNL treatment induced non‐apoptotic cytotoxicity, and augmented cell death induced by Ara‐C and venetoclax. Mechanistically, CNL reduced both venetoclax (Mcl‐1) and cytarabine (Chk1) drug‐resistant signaling pathways. Moreover, venetoclax and Ara‐C augmented the generation of endogenous pro‐death ceramide species, which was intensified with CNL. Taken together, CNL has the potential to be utilized as an adjuvant therapy to improve outcomes, potentially extending survival, in patients with AML. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. T-cell and natural killer-cell large granular lymphocyte leukemia neoplasias.
- Author
-
Watters, Rebecca J., Liu, Xin, and Loughran, Thomas P.
- Subjects
- *
T-cell lymphoma , *IMMUNE system , *LEUKEMIA , *CELL death , *IMMUNOSUPPRESSIVE agents - Abstract
Large granular lymphocyte (LGL) leukemia is a rare disorder of cytotoxic lymphocytes. LGL cells play an integral role in the immune system and are divided into two major lineages of CD3−natural killer (NK) cells and CD3++ T cells that circulate throughout the blood in search of infected cells, in which they will make contact through a receptor ligand and induce cell death. LGL cells are also programmed to undergo apoptosis after contact with an infected target cell; however, they continue to survive in individuals with LGL leukemia. This unchecked proliferation and cytotoxicity of LGLs in patients results in autoimmunity or malignancy. Rheumatoid arthritis is the most common autoimmune condition seen in individuals with LGL leukemia; however, LGL leukemia is associated with a wide spectrum of other autoimmune diseases. Patients may also suffer from other hematological conditions including hemolytic anemia, pure red cell aplasia, and neutropenia, which lead to recurrent bacterial infections. Currently, the only established treatment involves a low dose of an immunosuppressive regimen with methotrexate, in which 40-50% of patients are either resistant or do not respond. In order to establish new therapeutics it is important to understand the current state of LGL leukemia both in the clinic and in basic research. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
12. New clues to accrue on neutropenia in rheumatoid arthritis
- Author
-
Hellmich, Bernhard, Pinals, Robert S., Loughran, Thomas P., and Sullivan, Kathleen E.
- Published
- 2005
- Full Text
- View/download PDF
13. Characterization of HTLV envelope seroreactivity in large granular lymphocyte leukemia
- Author
-
Sokol, Lubomir, Agrawal, Deepak, and Loughran, Thomas P.
- Subjects
- *
HTLV , *LEUKEMIA , *CANCER , *CELL proliferation - Abstract
Abstract: T-cell large granular lymphocyte (T-LGL) leukemia is a rare chronic lymphoproliferative disorder of unknown etiology. We have previously reported that patients with T-LGL leukemia were seroreactive against BA21, a 34 amino acid peptide derived from HTLV-I envelope protein p21. We tested sera from 70 patients with T-LGL leukemia and found that 21/70 (30%) of them were seroreactive against fusion peptide GST-BA21. In control group of healthy blood donors 3/30 (10%) were seroreactive. We synthesized a set of overlapping peptides derived from BA21 and tested them against sera from patients. Only a single peptide (p21 env 417–430) showed reactivity. We then generated multiple fusion peptides consisting of 5–14 amino acid residues derived from this peptide and tested them against patient and control sera. Shortest peptide giving positive seroreactivity was octapeptide P8 (p21 env 418–425). Competitive Western blot assay with use of fusion peptides revealed that the minimal HTLV-I epitope responsible for seroreactivity found in patients with T-LGL leukemia is a decapeptide PP10 (p21 env 417–426). Protein Bank (NCBI) search did not reveal any significant homology between PP10 epitope and known human proteins. These results further define the epitope responsible for HTLV env seroreactivity observed in LGL leukemia. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
14. Large granular lymphocyte leukemia serum and corresponding hematological parameters reveal unique cytokine and sphingolipid biomarkers and associations with STAT3 mutations.
- Author
-
Olson, Kristine C., Moosic, Katharine B., Jones, Marieke K., Larkin, Paige M. K., Olson, Thomas L., Toro, Mariella F., Fox, Todd E., Feith, David J., and Loughran, Thomas P.
- Subjects
- *
LEUKEMIA , *CORNEAL dystrophies , *LYMPHOCYTES , *BLOOD serum analysis , *SERUM , *BIOMARKERS - Abstract
Large granular lymphocyte (LGL) leukemia is a rare hematological disorder with expansion of the T‐cell or natural killer (NK) cell lineage. Signal transducer and activator of transcription 3 (STAT3) exhibits somatic activating mutations in 30%‐40% of LGL leukemia cases. Transcriptional targets of STAT3 include inflammatory cytokines, thus previous studies have measured cytokine levels of LGL leukemia patients compared to normal donors. Sphingolipid metabolism is a growing area of cancer research, with efforts focused on drug discovery. To date, no studies have examined serum sphingolipids in LGL leukemia patients, and only one study compared a subset of cytokines between the T‐LGL and NK‐LGL subtypes. Therefore, here, we included both LGL leukemia subtypes with the goals of (a) measuring serum sphingolipids for the first time, (b) measuring cytokines to find distinctions between the subtypes, and (c) establishing relationships with STAT3 mutations and clinical data. The serum analyses identified cytokines (EGF, IP‐10, G‐CSF) and sphingolipids (SMC22, SMC24, SMC20, LysoSM) significantly different in the LGL leukemia group compared to normal donors. In a mixed STAT3 mutation group, D661Y samples exhibited the highest mean corpuscular volume (MCV) values. We explored this further by expanding the cohort to include larger groups of single STAT3 mutations. Male D661Y STAT3 samples had lower Hgb and higher MCV compared to wild type (WT) or Y640F counterparts. This is the first report examining large groups of individual STAT3 mutations. Overall, our results revealed novel serum biomarkers and evidence that D661Y mutation may show different clinical manifestation compared to WT or Y640F STAT3. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. Sphingosine kinase‐2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl‐1.
- Author
-
LeBlanc, Francis R., Pearson, Jennifer M., Tan, Su‐Fern, Cheon, HeeJin, Xing, Jeffrey C., Dunton, Wendy, Feith, David J., and Loughran, Thomas P.
- Subjects
- *
LEUKEMIA , *SPHINGOSINE , *CELLULAR control mechanisms , *LYMPHOCYTES , *APOPTOSIS - Abstract
Summary: Sphingolipid metabolism is increasingly recognised as a therapeutic target in cancer due to its regulation of cell proliferation and apoptosis. The sphingolipid rheostat is proposed to control cell fate through maintaining balance between pro‐apoptotic and pro‐survival sphingolipids. This balance is regulated by metabolising enzymes involved in sphingolipid production. One such enzyme, sphingosine kinase‐2 (SPHK2), produces pro‐survival sphingosine 1‐phosphate (S1P) by phosphorylation of pro‐apoptotic sphingosine. Elevated SPHK2 has been found in multiple cancer types and contributes to cell survival, chemotherapeutic resistance and apoptosis resistance. We have previously shown elevation of S1P in large granular lymphocyte (LGL) leukaemia serum and cells isolated from patients. Here, we examined SPHK2 expression in LGL leukaemia and found SPHK2 mRNA and protein upregulation in a majority of LGL leukaemia patient samples. Knockdown of SPHK2 with siRNA in LGL leukaemia cell lines decreased proliferation. Additionally, the use of ABC294640 or K145, both SPHK2‐specific inhibitors, decreased viability of LGL leukaemia cell lines. ABC294640 selectively induced apoptosis in LGL cell lines and freshly isolated LGL leukaemia patient cells compared to normal controls. Mechanistically, SPHK2 inhibition downregulated pro‐survival myeloid cell leukaemia‐1 (Mcl‐1) protein through proteasomal degradation. Targeting of SPHK2 therefore provides a novel therapeutic approach for the treatment of LGL leukaemia. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. Retroviral sero‐reactivity in LGL leukaemia patients and family members.
- Author
-
Nyland, Susan B., Feith, David J., Poss, Mary, Olson, Thomas L., Krissinger, Daniel J., Poiesz, Bernard J., Ruscetti, Francis W., and Loughran, Thomas P.
- Subjects
- *
CYTOTOXIC T cells , *PATIENT-family relations , *LEUKEMIA , *MEMBRANE proteins , *RHEUMATOID arthritis - Abstract
T‐cell large granular lymphocyte (T‐LGL) leukaemia is characterized by a clonal proliferation of cytotoxic T cells and is frequently associated with rheumatoid arthritis. Sera from some LGL leukaemia patients react to a portion of the human T‐cell leukaemia virus (HTLV‐1/2) transmembrane envelope protein, BA21, although HTLV‐1/2 infection is rare in LGL leukaemia patients. Here we show that family members, including spouses, of an LGL leukaemia patient had elevated LGL counts, BA21 reactivity and, additionally, recognition of HIV‐1 gp41. Thus, both LGL leukaemia patients and clinically normal contacts sharing the same environment have evidence of exposure to a retrovirus. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen.
- Author
-
Morad, Samy A.F., MacDougall, Matthew R., Abdelmageed, Noha, Kao, Li-Pin, Feith, David J., Tan, Su-Fern, Kester, Mark, Loughran, Thomas P., Wang, Hong-Gang, and Cabot, Myles C.
- Subjects
- *
ACUTE myeloid leukemia , *CERAMIDES , *TAMOXIFEN , *SPHINGOLIPIDS , *ESTROGEN antagonists - Abstract
Acute myelogenous leukemia (AML) is a hematological malignancy marked by the accumulation of large numbers of immature myeloblasts in bone marrow. The overall prognosis in AML is poor; hence, there is a pressing need to improve treatment. Although the sphingolipid (SL) ceramide demonstrates known cancer suppressor properties, it's mechanism of action is multifaceted. Our studies in leukemia and other cancers have demonstrated that when combined with the antiestrogen, tamoxifen, the apoptosis-inducting effect of ceramide is greatly enhanced. The goal of the present study was to establish whether a ceramide-tamoxifen regimen also affects autophagic-driven cellular responses in leukemia. Using the human AML cell line KG-1, we demonstrate that, unlike exposure to the single agents, combination C6-ceramide-tamoxifen upregulated LC3-II expression, inhibited the mTOR signaling pathway, and synergistically induced KG-1 cell death in an Atg5-dependent manner. In addition, colocalization of autophagosome and mitochondria, indicative of mitophagosome formation and mitophagy, was observed. Versatility of the drug regimen was confirmed by experiments in MV4-11 cells, a FLT3-ITD AML mutant. These results indicate that the C6-ceramide-tamoxifen regimen plays a pivotal role inducing autophagy in AML, and thus constitutes a novel therapeutic design. • Ceramide-tamoxifen regimen affects autophagic-driven responses in human AML cells. • Cell death with the regimen was Atg5-dependent and accompanied by mitophagy. • Inhibition of cell growth was associated with inhibition of mTOR signaling. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
18. Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes.
- Author
-
Olson, Kristine C., Kulling Larkin, Paige M., Signorelli, Rossana, Hamele, Cait E., Olson, Thomas L., Conaway, Mark R., Feith, David J., and Loughran, Thomas P.
- Subjects
- *
VITAMIN D , *STAT proteins , *CYTOKINES , *INFLAMMATION , *KILLER cells , *INTERLEUKIN-10 - Abstract
Graphical abstract Highlights • NKL cell line used as a model for NK cell large granular lymphocyte leukemia. • Exogenous IL-2 causes tyrosine phosphorylation in STAT1 through 6 in NKL cells. • NKL co-treated with IL-2 and calcitriol (vitamin D) or EB1089 (calcitriol analog). • Calcitriol or EB1089 deactivate STAT1 and 3 in NKL cells and NK-LGLL patient PBMCs. • 15 cytokines significantly altered in NK-LGLL; EB1089 decreased 3 cytokines in NKL. Abstract Calcitriol, the active form of vitamin D, has been well documented to act directly on immune cells and malignant cells. Activated T cells are one of the best characterized targets of calcitriol, with effects including decreasing inflammatory cytokine output and promoting anti-inflammatory cytokine production. However, the effects of calcitriol on natural killer (NK) cells are less clear. Reports suggest that only immature NK cell populations are affected by calcitriol treatment resulting in impaired cytotoxic function and cytokine production, while mature NK cells may have little or no response. NK cell large granular lymphocyte leukemia (NK-LGLL) is a rare leukemia with CD3-CD16+CD56+NK cell clonal expansion. The current standard treatments are immunosuppressant therapies, which are not curative. The Janus kinase (JAK) – signal transducer and activator of transcription (STAT) pathway is hyperactivated in LGLL and is one pathway of interest in new drug target investigations. We previously demonstrated the ability of calcitriol to decrease STAT1 tyrosine 701 (p-STAT1) and STAT3 tyrosine 705 (p-STAT3) phosphorylation as well as inflammatory cytokine output of T cell large granular lymphocyte leukemia cells, but did not determine the effects of calcitriol on NK-LGLL. Therefore, in the present study, we investigated whether NKL cells, a model of NK-LGLL, and NK-LGLL patient peripheral blood mononuclear cells (PBMCs) are susceptible to treatment with calcitriol or seocalcitol (EB1089), a potent analog of calcitriol. NKL cells are dependent on interleukin (IL)-2 for survival and we show here for the first time that treatment with IL-2 induced tyrosine phosphorylation of STATs 1 through 6. Both calcitriol and EB1089 caused significant upregulation of the vitamin D receptor (VDR). IL-2 induction of p-STAT1 and p-STAT3 phosphorylation was significantly decreased after calcitriol or EB1089 treatment. Additionally, IL-10, interferon (IFN)-γ, and FMS-like tyrosine kinase 3 ligand (Flt-3L) extracellular output was significantly decreased at 100 nM EB1089 and intracellular IL-10 was decreased with either calcitriol or EB1089 treatment. We treated NK-LGLL patient PBMCs with calcitriol or EB1089 and found decreased p-STAT1 and p-STAT3 while VDR increased, which matched the NKL cell line data. We then measured 75 serum cytokines in NK-LGLL patients (n = 8) vs. age- and sex-matched normal healthy donors (n = 8), which is the first serum cytokine study for this LGLL subtype. We identified 15 cytokines, including IL-10 and Flt-3L, which were significantly different between normal donors and NK-LGLL patients. Overall, our results suggest that activating the vitamin D pathway could be a mechanism to decrease STAT1 and 3 activation and inflammatory cytokine output in NK-LGLL patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
19. Vitamin D decreases STAT phosphorylation and inflammatory cytokine output in T-LGL leukemia.
- Author
-
Olson, Kristine C., Kulling, Paige M., Olson, Thomas L., Tan, Su-Fern, Rainbow, Rebecca J., Feith, David J., and Loughran, Thomas P.
- Abstract
Large granular lymphocyte leukemia (LGLL) is a rare incurable chronic disease typically characterized by clonal expansion of CD3+ cytotoxic T-cells. Two signal transducer and activator of transcription factors, STAT1 and STAT3, are constitutively active in T-LGLL. Disruption of this activation induces apoptosis in T-LGLL cells. Therefore, considerable efforts are focused on developing treatments that inhibit STAT activation. Calcitriol, the active form of vitamin D, has been shown to decrease STAT1 and STAT3 phosphorylation in cancer cell lines and autoimmune disease mouse models. Thus, we investigated whether calcitriol could be a valid therapeutic for T-LGLL. Calcitriol treatment of the TL-1 cell line (model of T-LGLL) led to decreased phospho-Y701 STAT1 and phospho-Y705 STAT3 and increased vitamin D receptor (VDR) levels. Doses of 10 and 100 nM calcitriol also significantly decreased the inflammatory cytokine IFN-γ in the TL-1 cell line. The overall cell viability did not change when the TL-1 cell line was treated with 0.1 to 1000 nM calcitriol. Studies with primary T-LGLL patient peripheral blood mononuclear cells showed that the majority of T-LGLL patients have detectable VDR and activated STATs in contrast to normal donor controls. Treatment of primary T-LGLL patient cells with calcitriol recapitulated findings from the TL-1 cell line. Overall, our results suggest that calcitriol may reprogram T-cells to decrease essential STAT activation and pro-inflammatory cytokine output. These data support further investigation into calcitriol as an experimental therapeutic for T-LGLL. [ABSTRACT FROM PUBLISHER]
- Published
- 2017
- Full Text
- View/download PDF
20. Genome-wide mapping of histone H3K9me2 in acute myeloid leukemia reveals large chromosomal domains associated with massive gene silencing and sites of genome instability.
- Author
-
Salzberg, Anna C., Harris-Becker, Abigail, Popova, Evgenya Y., Keasey, Nikki, Loughran, Thomas P., Claxton, David F., and Grigoryev, Sergei A.
- Subjects
- *
HISTONE demethylases , *ACUTE myeloid leukemia , *GENE mapping , *GENE silencing , *PHARMACOLOGY , *HETEROCHROMATIN , *HEMATOPOIETIC stem cells - Abstract
A facultative heterochromatin mark, histone H3 lysine 9 dimethylation (H3K9me2), which is mediated by histone methyltransferases G9a/GLP (EHMT2/1), undergoes dramatic rearrangements during myeloid cell differentiation as observed by chromatin imaging. To determine whether these structural transitions also involve genomic repositioning of H3K9me2, we used ChIP-sequencing to map genome-wide topography of H3K9me2 in normal human granulocytes, normal CD34+ hematopoietic progenitors, primary myeloblasts from acute myeloid leukemia (AML) patients, and a model leukemia cell line K562. We observe that H3K9me2 naturally repositions from the previously designated “repressed” chromatin state in hematopoietic progenitors to predominant association with heterochromatin regions in granulocytes. In contrast, AML cells accumulate H3K9me2 on previously undefined large (> 100 Kb) genomic blocks that are enriched with AML-specific single nucleotide variants, sites of chromosomal translocations, and genes downregulated in AML. Specifically, the AML-specific H3K9me2 blocks are enriched with genes regulated by the proto-oncogene ERG that promotes stem cell characteristics. The AML-enriched H3K9me2 blocks (in contrast to the heterochromatin-associated H3K9me2 blocks enriched in granulocytes) are reduced by pharmacological inhibition of the histone methyltransferase G9a/GLP in K562 cells concomitantly with transcriptional activation of ERG and ETS1 oncogenes. Our data suggest that G9a/GLP mediate formation of transient H3K9me2 blocks that are preserved in AML myeloblasts and may lead to an increased rate of AML-specific mutagenesis and chromosomal translocations. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
21. Vitamin D in hematological disorders and malignancies.
- Author
-
Kulling, Paige M., Olson, Kristine C., Olson, Thomas L., Feith, David J., and Loughran, Thomas P.
- Subjects
- *
VITAMIN D , *HEMATOLOGIC malignancies , *CARCINOGENESIS , *TREATMENT effectiveness , *CELL proliferation , *CANCER cells - Abstract
Commonly known for its critical role in calcium homeostasis and bone mineralization, more recently vitamin D has been implicated in hematological cancer pathogenesis and shows promise as an anti-cancer therapy. Serum levels of 25( OH)D3, the precursor to the active form of vitamin D, calcitriol, are frequently lower in patients with hematological disease compared to healthy individuals. This often correlates with worse disease outcome. Furthermore, diseased cells typically highly express the vitamin D receptor, which is required for many of the anti-cancer effects observed in multiple in vivo and in vitro cancer models. In abnormal hematological cells, vitamin D supplementation promotes apoptosis, induces differentiation, inhibits proliferation, sensitizes tumor cells to other anti-cancer therapies, and reduces the production of pro-inflammatory cytokines. Although the dosage of vitamin D required to achieve these effects may induce hypercalcemia in humans, analogs and combinatorial treatments have been developed to circumvent this side effect. Vitamin D and its analogs are well tolerated in clinical trials, and thus, further investigation into the use of these agents in the clinic is warranted. Here, we review the current literature in this field. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
22. Fludarabine, idarubicin, and cytarabine regimen together with TKI followed by haploidentical hematopoietic stem cell transplantation, a success for relapsed Ph+ acute lymphoblastic leukemia.
- Author
-
Sang, Wei, Wang, Ying, Zhang, Cong, Yan, Dongmei, Niu, Mingshan, Yang, Chun, Liu, Xia, Sun, Cai, Zhang, Zhe, Loughran, Thomas P., and Xu, Kailin
- Subjects
- *
LYMPHOBLASTIC leukemia , *LYMPHOCYTIC leukemia , *STEM cell transplantation , *CELL transplantation , *ANTINEOPLASTIC agents , *CYTARABINE , *IDARUBICIN , *FLUDARABINE - Abstract
Key Clinical Message In this report, a case of relapsed Ph+ ALL was remedied by reinduction, and consolidation regimen of TKI and Flu+ Ara-C+ IDA ( FLAI) combination, followed by haploidentical SCT. Results suggest that FLAI together with TKI and subsequently with haploidentical SCT could be applied for relapsed Ph+ ALL. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
23. Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia.
- Author
-
LeBlanc, Francis R, Liu, Xin, Hengst, Jeremy, Fox, Todd, Calvert, Valerie, Petricoin, Emanuel F, Yun, Jong, Feith, David J, and Loughran, Thomas P
- Published
- 2015
- Full Text
- View/download PDF
24. Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK- LGL leukaemia.
- Author
-
Sun, Xiaoshen, Hasanali, Zainul S., Chen, Allshine, Zhang, Dianzheng, Liu, Xin, Wang, Hong‐Gang, Feith, David J., Loughran, Thomas P., and Xu, Kailin
- Subjects
- *
HYDROXAMIC acids , *ANTINEOPLASTIC agents , *LEUKEMIA , *KILLER cells , *APOPTOSIS , *HISTONE deacetylase , *PATIENTS - Abstract
Natural killer ( NK) large granular lymphocyte ( LGL) leukaemia features a clonal proliferation of CD3− NK cells that can be classified into either aggressive or chronic categories. The NKL cell line, derived from an aggressive Asian NK cell leukaemia, and patient samples from chronic NK- LGL leukaemia were used in our study to probe for synergistic efficacy of the epigenetic drugs vorinostat ( SAHA) and cladribine in this disease. We demonstrate that histone deacetylases ( HDACs) are over-expressed in both aggressive and chronic NK leukaemia. Administration of the HDAC inhibitor SAHA reduces class I and II HDAC expression and enhances histone acetylation in leukaemic NK cells. In vitro combination treatment with SAHA and cladribine dose-dependently exerts synergistic cytotoxic and apoptotic effects on leukaemic NK cells. Expression profiling of apoptotic regulatory genes suggests that both compounds led to caspase-dependent apoptosis through activation of intrinsic mitochondrial and extrinsic death receptor pathways. Collectively, these data show that combined epigenetic therapy, using HDAC and DNA methyltransferase inhibitors, may be a promising therapeutic approach for NK- LGL leukaemia. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
25. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.
- Author
-
Doi, Kenichiro, Gowda, Krishne, Liu, Qiang, Lin, Jyh-Ming, Sung, Shen-Shu, Dower, Christopher, Claxton, David, Loughran, Thomas P, Amin, Shantu, and Wang, Hong-Gang
- Published
- 2014
- Full Text
- View/download PDF
26. Transformed aggressive γδ-variant T-cell large granular lymphocytic leukemia with acquired copy neutral loss of heterozygosity at 17q11.2q25.3 and additional aberrations.
- Author
-
Zhang, Ling, Ramchandren, Radhakrishnan, Papenhausen, Peter, Loughran, Thomas P., and Sokol, Lubomir
- Subjects
- *
T-cell lymphoma , *HETEROZYGOSITY , *LEUKEMIA , *CYTOGENETICS , *TONSIL diseases , *PATIENTS - Abstract
T-cell large granular lymphocytic leukemia (T-LGLL) is a rare indolent lymphoproliferative disorder characterized by cytopenias, splenomegaly, and various degrees of T-cell lymphocytosis, due to a clonal expansion of CD8-positive cytotoxic T-cells. Phenotypic variants of T-LGLL include CD4+/CD8− T-cells, with dual CD4−/CD8−/γδ+ T-cells being even rarer. Cytogenetic abnormalities in T-LGLL have rarely been reported, and there is scientific debate regarding the existence of aggressive or transformed variants of T-LGLL. We report a patient with T-LGLL, γδ variant, with nearly 20-year-long duration of cytopenias before transformation to an unusual clinical scenario, manifesting with marked lymphocytosis >100 × 109/L and infiltration of lymph nodes, tonsils, and subcutaneous tissue. Single-nucleotide polymorphism assays revealed acquired copy neutral loss of heterozygosity at 17q and deletion of 3p21.31, in addition to trisomy 5, monosomy X, and monosomy 21. These genetic abnormalities provided a better understanding of the molecular nature and the potentiality of disease transformation. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
27. Splenic extramedullary hematopoiesis in a patient receiving intermittently administered granulocyte colony-stimulating factor.
- Author
-
Litam, Patrick P., Friedman, Henry D., Loughran, Thomas P., Litam, P P, Friedman, H D, and Loughran, T P Jr
- Subjects
- *
HEMATOPOIESIS , *SPLENIC vein , *GRANULOCYTES , *DISEASES , *THERAPEUTICS , *COMPARATIVE studies , *DRUG administration , *GRANULOCYTE-colony stimulating factor , *LYMPHOMAS , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *SPLEEN , *EVALUATION research - Abstract
Describes a case of splenic extramedullary hematopoiesis that occurred in a patient receiving intermittent granulocyte colony-stimulating factor therapy. Details on the case report; Discussion on the case.
- Published
- 1993
- Full Text
- View/download PDF
28. Developing an in vitro model of T cell type of large granular lymphocyte leukemia.
- Author
-
Ren, Tong, Yang, Jun, Broeg, Katie, Liu, Xin, Loughran, Thomas P., and Cheng, Hua
- Subjects
- *
LYMPHOCYTIC leukemia , *T cells , *CD8 antigen , *SYNTAXINS , *HTLV-II (Virus) , *GENE expression - Abstract
Abstract: We developed a strategy that can prolong in vitro growth of T cell type of large granular lymphocyte (T-LGL) leukemia cells. Primary CD8+ lymphocytes from T-LGL leukemia patients were stably transduced with the retroviral tax gene derived from human T cell leukemia virus type 2. Expression of Tax overrode replicative senescence and promoted clonal expansion of the leukemic CD8+ T cells. These cells exhibit features characteristic of leukemic LGL, including resistance to FasL-mediated apoptosis, sensitivity to the inhibitors of sphingosine-1-phosphate receptor and IκB kinases as well as expression of cytotoxic gene products such as granzyme B, perforin and IFNγ. Collectively, these results indicate that this leukemia cell model can duplicate the main phenotype and pathophysiological characteristics of the clinical isolates of T-LGL leukemia. This model should be useful for investigating molecular pathogenesis of the disease and for developing new therapeutics targeting T-LGL leukemia. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
29. Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia.
- Author
-
Watters, Rebecca J., Fox, Todd E., Tan, Su-Fern, Shanmugavelandy, Sriram, Choby, Jacob E., Broeg, Kathleen, Liao, Jason, Kester, Mark, Cabot, Myles C., Loughran, Thomas P., and Liu, Xin
- Subjects
- *
KILLER cells , *CYTOLOGICAL research , *LEUKEMIA , *SPHINGOLIPIDS , *GLUCOSYLCERAMIDES , *URIDINE diphosphate - Abstract
Natural killer (NK) cell leukemia is characterized by clonal expansion of CD3 − NK cells and comprises both chronic and aggressive forms. Currently no effective treatment exists, thus providing a need for identification of novel therapeutics. Lipidomic studies revealed a dysregulated sphingolipid metabolism as evidenced by decreased levels of overall ceramide species and increased levels of cerebrosides in leukemic NK cells, concomitant with increased glucosylceramide synthase (GCS) expression. GCS, a key enzyme of this pathway, neutralizes pro-apoptotic ceramide by transfer of a uridine diphosphate (UDP)-glucose. Thus, we treated both rat and human leukemic NK cells in combination with: (1) exogenous C6-ceramide nanoliposomes in order to target mitochondria and increase physiological pro-apoptotic levels of long chain ceramide, and (2) 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP), an inhibitor of GCS. Co-administration of C6-ceramide nanoliposomes and PPMP elicited an increase in endogenous long-chain ceramide species, which led to cellular apoptosis in a synergistic manner via the mitochondrial intrinsic cell death pathway in leukemic NK cells. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
30. Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: Results of a bone marrow failure consortium study
- Author
-
Nyland, Susan Bell, Krissinger, Daniel J., Clemente, Michael J., Irby, Rosalyn B., Baab, Kendall Thomas, Jarbadan, Nancy Ruth, Sokol, Lubomir, Schaefer, Eric, Liao, Jason, Cuthbertson, David, Epling-Burnette, Pearlie, Paquette, Ronald, List, Alan F., Maciejewski, Jaroslaw P., and Loughran, Thomas P.
- Subjects
- *
APLASTIC anemia , *LYMPHOCYTES , *LEUKEMIA , *EPITOPES , *ANTIGENS , *MYELODYSPLASTIC syndromes , *PAROXYSMAL hemoglobinuria , *BONE marrow - Abstract
Abstract: Large granular lymphocyte (LGL) leukemia is characterized by clonal expansion of antigen-activated cytotoxic T cells (CTL). Patients frequently exhibit seroreactivity against a human T-cell leukemia virus (HTLV) epitope, BA21. Aplastic anemia, paroxysmal nocturnal hemoglobinuria and myelodysplastic syndrome are bone marrow failure diseases that can also be associated with similar aberrant CTL activation (LGL-BMF). We identified a BA21 peptide that was specifically reactive with LGL leukemia sera and found significantly elevated antibody reactivity against the same peptide in LGL-BMF sera. This finding of shared seroreactivity in LGL-BMF conditions and LGL leukemia suggests that these diseases might share a common pathogenesis. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
31. The effect of selenium enrichment on baker's yeast proteome
- Author
-
El-Bayoumy, Karam, Das, Arunangshu, Russell, Stephen, Wolfe, Steven, Jordan, Rick, Renganathan, Kutralanathan, Loughran, Thomas P., and Somiari, Richard
- Subjects
- *
SELENIUM , *YEAST , *PROTEOMICS , *DIETARY supplements , *PROSTATE cancer , *WESTERN immunoblotting - Abstract
Abstract: The use of regular yeast (RY) and selenium-enriched yeast (SEY) as dietary supplement is of interest because the Nutritional Prevention of Cancer (NPC) trial revealed that SEY but not RY decreased the incidence of prostate cancer (PC). Using two-dimensional difference in gel electrophoresis (2D-DIGE)-tandem mass spectrometry (MS/MS) approach, we performed proteomic analysis of RY and SEY to identify proteins that are differentially expressed as a result of selenium enrichment. 2D-DIGE revealed 96 candidate protein spots that were differentially expressed (p≤0.05) between SEY and RY. The 96 spots were selected, sequenced by LC/MS/MS and 37 proteins were unequivocally identified. The 37 identified proteins were verified with ProteinProphet software and mapped to existing Gene Ontology categories. Furthermore, the expression profile of 5 of the proteins with validated or putative roles in the carcinogenesis process, and for which antibodies against human forms of the proteins are available commercially was verified by western analysis. This study provides evidence for the first time that SEY contains higher levels of Pyruvate Kinase, HSP70, and Elongation factor 2 and lower levels of Eukaryotic Translation Initiation Factor 5A-2 and Triosephosphate Isomerase than those found in RY. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
32. Dynamical and Structural Analysis of a T Cell Survival Network Identifies Novel Candidate Therapeutic Targets for Large Granular Lymphocyte Leukemia.
- Author
-
Saadatpour, Assieh, Rui-Sheng Wang, Aijun Liao, Xin Liu, Loughran, Thomas P., Albert, István, and Albert, Réka
- Subjects
- *
LYMPHOCYTES , *CHRONIC diseases , *T cells , *BIOCHEMISTRY , *SIGNAL processing - Abstract
The blood cancer T cell large granular lymphocyte (T-LGL) leukemia is a chronic disease characterized by a clonal proliferation of cytotoxic T cells. As no curative therapy is yet known for this disease, identification of potential therapeutic targets is of immense importance. In this paper, we perform a comprehensive dynamical and structural analysis of a network model of this disease. By employing a network reduction technique, we identify the stationary states (fixed points) of the system, representing normal and diseased (T-LGL) behavior, and analyze their precursor states (basins of attraction) using an asynchronous Boolean dynamic framework. This analysis identifies the T-LGL states of 54 components of the network, out of which 36 (67%) are corroborated by previous experimental evidence and the rest are novel predictions. We further test and validate one of these newly identified states experimentally. Specifically, we verify the prediction that the node SMAD is over-active in leukemic T-LGL by demonstrating the predominant phosphorylation of the SMAD family members Smad2 and Smad3. Our systematic perturbation analysis using dynamical and structural methods leads to the identification of 19 potential therapeutic targets, 68% of which are corroborated by experimental evidence. The novel therapeutic targets provide valuable guidance for wet-bench experiments. In addition, we successfully identify two new candidates for engineering long-lived T cells necessary for the delivery of virus and cancer vaccines. Overall, this study provides a bird's-eye-view of the avenues available for identification of therapeutic targets for similar diseases through perturbation of the underlying signal transduction network. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
33. Dysregulation of sphingolipid metabolism in cancer.
- Author
-
Ryland, Lindsay K., Fox, Todd E., Liu, Xin, Loughran, Thomas P., and Kester, Mark
- Published
- 2011
- Full Text
- View/download PDF
34. Bif-1 regulates Atg9 trafficking by mediating the fission of Golgi membranes during autophagy.
- Author
-
Takahashi, Yoshinori, Meyerkord, Cheryl L., Hori, Tsukasa, Runkle, Kristin, Fox, Todd E., Kester, Mark, Loughran, Thomas P., and Hong-Gang Wang
- Published
- 2011
- Full Text
- View/download PDF
35. Liver Injury During Acute Pancreatitis: The Role of Pancreatitis-Associated Ascitic Fluid (PAAF), p38-MAPK, and Caspase-3 in Inducing Hepatocyte Apoptosis
- Author
-
Yang, Jun, Fier, Adam, Carter, Yvette, Liu, Gouqing, Epling-Burnette, P.K., Bai, Fanqi, Loughran Jr., Thomas P., Mastorides, Stephen, Norman, James G., Murr, Michel M., and Loughran, Thomas P Jr
- Subjects
- *
LIVER injuries , *PANCREATITIS , *CYTOKINES , *APOPTOSIS - Abstract
We have demonstrated that pancreatitis-associated ascitic fluid contributes to hepatocyte injury during acute pancreatitis; a phenomenon independent of ascites'' enzymatic content and Kupffer cell-derived cytokines. Our aim is to characterize the mechanisms of pancreatitis-associated ascitic fluid induced hepatocyte death. NIH mice were injected intraperitoneally with pathogen-free pancreatitis-associated ascitic fluid. Twenty-four hours later, serum AST, ALT, LDH, and hepatocyte apoptosis (TUNEL) were measured. Human hepatocytes (CCL-13) were treated with pancreatitis-associated ascitic fluid ±SB203580 or caspase-3 inhibitor-II. Mitochondrial membrane integrity was determined by DiOC6 staining. Apoptosis was measured by TUNEL staining and flow cytometry after dual labeling with Annexin-V/7-AAD. Data are mean ± SEM of triplicates. Pancreatitis-associated ascitic fluid increased serum AST, ALT, LDH, and apoptotic cells in the mouse liver (all P < 0.03 vs. sham). In CCL-13 cells, pancreatitis-associated ascitic fluid induced a time and dose-dependent increase in apoptosis, in addition to p38-MAPK phosphorylation (P = 0.02 vs. control), caspase-3 cleavage (P < 0.03 vs. control) and decreased DiOC6 mitochondrial staining (P < 0.01 vs. control). Both caspase-3 inhibitor-II and SB203580 decreased apoptosis, but the former had no effect on DiOC6 staining. Pancreatitis-associated ascitic fluid induces liver injury and hepatocyte apoptosis by activating p38-MAPK and caspase-3 dependent pro-apoptotic pathways. ( J Gastrointest Surg 2003;7:200–208.) [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
36. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
- Author
-
Mei Huang, Dorsey, Jay F., Epling-Burnette, P.K., Nimmanapalli, Ramadevi, Landowski, Terry H., Mora, Linda B., Niu, Guilian, Sinibaldi, Dominic, Bai, Fanqi, Kraker, Alan, Hua Yu, Moscinski, Lynn, Sheng Wei, Djeu, Julie, Dalton, William S., Bhalla, Kapil, Loughran, Thomas P., Jie Wu, and Jove, Richard
- Subjects
- *
MYELOID leukemia genetics , *CANCER genetics - Abstract
Presents a study which demonstrated the inhibition by PD180970 of the Stat5 DNA-binding activity in the human K562 chronic myelogenous leukemia cell line. Review of related literature; Methodology; Results and discussion.
- Published
- 2002
- Full Text
- View/download PDF
37. Multidrug resistance analysis in lymphoproliferative disease of large granular lymphocytes.
- Author
-
Lamy, Thierry, Drenou, Bernard, Fardel, Olivier, Amiot, Laurence, Grulois, Isabelle, Le Prise, Pierre-Yves, Loughran, Thomas P., and Fauchet, Renee
- Subjects
- *
MULTIDRUG resistance , *LYMPHOPROLIFERATIVE disorders , *LYMPHOCYTES - Abstract
Multi-drug resistance (MDR) phenotype contributes to the ineffectiveness of chemotherapy. P-glycoprotein (PgP) and lung resistance protein (LRP) are proteins implicated in chemoresistance. We analysed the expression of PgP and LRP respectively in 17 and 15 cases of lymphoproliferative disease of granular lymphocytes (LDGL) including 10 cases of clonal large granular lymphocytic (LGL) leukaemia, six cases of oligoclonal (n = 5) and polyclonal (n = 1) CD3+ lymphoproliferation and one case of CD3- NK lymphocytosis. Functional PgP activity, as determined by Rh123 dye efflux assay, was found in all the patients. The mean percentage of effluxing cells was 47 ± 22%, compared to 35 ± 8% on normal lymphocytes (P < 0.04). The efflux was blocked in the presence of verapamil, a PgP revertant agent. A high proportion of CD57+ cells (66 ± 10%) from these patients expelled Rh123. Functional PgP activity was associated with expression of MDR1 mRNA. By using immunocytochemistry, LRP expression was detected in 11/15 patients (73%). 7/10 LGL leukaemia patients presented a LRP+/Efflux+ phenotype and 5/7 had LRP+/Efflux+/MDR1 mRNA+ phenotype. These findings suggest that the PgP+/LRP+ phenotype is frequently observed in LDGL. Its clinical relevance in aggressive cases remains to be determined. [ABSTRACT FROM AUTHOR]
- Published
- 1998
- Full Text
- View/download PDF
38. Whole Genome Sequencing of Spontaneously Occurring Rat Natural Killer Large Granular Lymphocyte Leukemia Identifies JAK1 Somatic Activating Mutation.
- Author
-
Wang, T. Tiffany, Yang, Jun, Dighe, Shubha, Schmachtenberg, Matthew W., Leigh, Nathan T., Farber, Emily, Onengut-Gumuscu, Suna, Feith, David J., Ratan, Aakrosh, Loughran, Thomas P., and Olson, Thomas L.
- Subjects
- *
ALLELES , *ANIMAL experimentation , *CELL lines , *CELLULAR signal transduction , *GENOMES , *KILLER cells , *LYMPHOCYTIC leukemia , *GENETIC mutation , *PHOSPHOPROTEINS , *PHOSPHORYLATION , *PROTEINS , *RATS , *SEQUENCE analysis , *IN vivo studies - Abstract
Large granular lymphocyte (LGL) leukemia arises spontaneously in elderly Fischer (F344) rats. This rodent model has been shown to emulate many aspects of the natural killer (NK) variant of human LGL leukemia. Previous transplantation of leukemic material into young F344 rats resulted in several strains of rat NK (RNK) primary leukemic cells. One strain, RNK-16, was adapted into the RNK-16 cell line and established as an aggressive NK-LGL leukemia model. Whole genome sequencing of the RNK-16 cell line identified 255,838 locations where the RNK16 had an alternate allele that was different from F344, including a mutation in Jak1. Functional studies showed Jak1 Y1034C to be a somatic activating mutation that mediated increased STAT signaling, as assessed by phosphoprotein levels. Sanger sequencing of Jak1 in RNK-1, -3, -7, and -16 found only RNK-16 to harbor the Y1034C Jak1 mutation. In vivo studies revealed that rats engrafted with RNK-16 primary material developed leukemia more rapidly than those engrafted with RNK-1, -3, and -7. Additionally, ex vivo RNK-16 spleen cells from leukemic rats exhibited increased STAT1, STAT3, and STAT5 phosphorylation compared to other RNK strains. Therefore, we report and characterize a novel gain-of-function Jak1 mutation in a spontaneous LGL leukemia model that results in increased downstream STAT signaling. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
39. Retrovirus insertion site analysis of LGL leukemia patient genomes.
- Author
-
Li, Weiling, Yang, Lei, Harris, Robert S., Lin, Lin, Olson, Thomas L., Hamele, Cait E., Feith, David J., Loughran, Thomas P., and Poss, Mary
- Subjects
- *
LEUKEMIA , *HUMAN genome , *POPULATION , *CELL proliferation , *BLOOD group antigens , *GENOMES - Abstract
Background: Large granular lymphocyte (LGL) leukemia is an uncommon cancer characterized by sustained clonal proliferation of LGL cells. Antibodies reactive to retroviruses have been documented in the serum of patients with LGL leukemia. Culture or molecular approaches have to date not been successful in identifying a retrovirus. Methods: Because a retrovirus must integrate into the genome of an infected cell, we focused our efforts on detecting a novel retrovirus integration site in the clonally expanded LGL cells. We present a new computational tool that uses long-insert mate pair sequence data to search the genome of LGL leukemia cells for retrovirus integration sites. We also utilize recently published methods to interrogate the status of polymorphic human endogenous retrovirus type K (HERV-K) provirus in patient genomes. Results: Our data show that there are no new retrovirus insertions in LGL genomes of LGL leukemia patients. However, our insertion call tool did detect four HERV-K provirus integration sites that are polymorphic in the human population but absent from the human reference genome, hg19. To determine if the prevalence of these or other polymorphic proviral HERV-Ks differed between LGL leukemia patients and the general population, we used a recently developed tool that reports sites in the human genome occupied by a known proviral HERV-K. We report that there are significant differences in the number of polymorphic HERV-Ks in the genomes of LGL leukemia patients of European origin compared to individuals with European ancestry in the 1000 genomes (KGP) data. Conclusions: Our study confirms that the clonal expansion of LGL cells in LGL leukemia is not driven by the integration of a new infectious or endogenous retrovirus, although we do not rule out that these cells are responding to retroviral antigens produced in other cell types. However, our computational analyses revealed that the genomes of LGL leukemia patients carry a higher burden of polymorphic HERV-K proviruses compare to individuals from KGP of European ancestry. Our research emphasizes the merits of comprehensive genomic assessment of HERV-K in cancer samples and suggests that further analyses to determine contributions of HERV-K to LGL leukemia are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.